Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Meningioma 7Brain Neoplasms 6Leukemia, Myeloid, Acute 5Head and Neck Neoplasms 5Squamous Cell Carcinoma of Head and Neck 4Neoplasms 3Glioblastoma 3Stomach Neoplasms 2Myeloproliferative Disorders 2Myelodysplastic Syndromes 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid, Chronic-Phase 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Leukemia 2Laryngeal Neoplasms 2Gliosarcoma 2Esophageal Neoplasms 2Central Nervous System Neoplasms 2Thyroid Carcinoma, Anaplastic 1Thrombocytosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Pharyngeal Neoplasms 1Paranasal Sinus Neoplasms 1Papillomavirus Infections 1Pancreatic Neoplasms 1Oropharyngeal Neoplasms 1Nose Neoplasms 1Nasopharyngeal Neoplasms 1Myelodysplastic-Myeloproliferative Diseases 1

Interventions

Gemcitabine 295Fluorouracil 82Oxaliplatin 81130-nm albumin-bound paclitaxel 68Capecitabine 60Leucovorin 56Albumin-Bound Paclitaxel 54Radiotherapy 51Irinotecan 44Taxes 37Cisplatin 36Erlotinib Hydrochloride 34Radiosurgery 33pembrolizumab 29Docetaxel 27S 1 (combination) 26Bevacizumab 23folfirinox 22Nivolumab 21Magnetic Resonance Spectroscopy 17Cyclophosphamide 17Cetuximab 17irinotecan sucrosofate 16Radiation 16Drug Therapy 15Surgical Procedures, Operative 14Specimen Handling 11Biopsy 11durvalumab 10Paclitaxel 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Pancreatic Neoplasms × Hydroxyurea × Clear all
NCT00019474 2018-09-14

Combination Chemotherapy Plus Interferon Alfa Followed by Filgrastim in Treating Patients With Gastrointestinal Tract Cancer

Montefiore Medical Center

Phase 2 Completed
60 enrolled
Gastrointestinal

Bile Duct Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡